<DOC>
	<DOCNO>NCT00351195</DOCNO>
	<brief_summary>Various cytotoxic agent evaluate advanced hepatocellular carcinoma , response rate low significant toxicity , often due parenchymal liver disease . The three agent etoposide , oxaliplatin capecitabine sparse efficacy single agent , combination may act synergistically acceptable toxicity profile .</brief_summary>
	<brief_title>Etoposide , Oxaliplatin Capecitabine Advanced Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description>Design : Open phase II study . Purpose : Response rate combination etoposide , oxaliplatin capecitabine give every 3 week outpatient basis . Secondary endpoint safety , time progression survival Treatment : Etoposide administer intravenously 100 mg/m2 day 1 orally 200 mg/m2 day 2 3 . Capecitabine ( Xeloda ) administer 1000 mg/m2 twice daily 12 hour interval two week one week Oxaliplatin administer intravenously 100 mg/m2 day 1 cycle 2 hour infusion . One cycle 3 week .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Histologically verify intra extrahepatic inoperable hepatocellular carcinoma hyperdense liver lesion compute tomography concurrent elevate alphafetoprotein &gt; 400 ng/ml PS 02 Age 1875 Life expectancy &gt; 12 week Normal bone marrow function ( neutrophile &gt; 1,5 x 109/l platelet &gt; 100 x 109/l ) Bilirubin &lt; 2 x UNL Transaminases &lt; 3 x UNL Normal renal function , CrEDTA clearance &gt; 50 ml/min No chemotherapy , radiotherapy immunotherapy 4 week prior inclusion No uncontrolled , severe concurrent medical disease Fertile woman must negative pregnancy test Fertile woman must use adequate contraceptive 3 month trial exposure Signed informed consent Chemotherapy , radiotherapy immunotherapy 4 week prior inclusion Experimental therapy &lt; 8 week prior inclusion Known DPDdeficiency Known neuropathy Uncontrolled , severe concurrent medical disease Prior malignancy last 5 year , except nonmelanoma skin cancer carcinoma situ cervix uterus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Capecitabine</keyword>
</DOC>